Pamidronate Treatment in Patients with Tumor-Associated Hypercalcemia: Pharmacological Effects and Pharmacokinetics

• Published in: Endocrine Journal 1994, Vol.41(6), pp.655-661
• Main Authors: OISO, YUTAKA, TOMITA, AKIO, HASEGAWA, HARUHIKO, ARIYOSHI, YUTAKA, NIINOMI, MITSURO, YAMAMOTO, MASAHIRO, TAKANO, TSUNENORI, SAKIYAMA, NORIHISA
• Format: Article
• Language: English
• Subjects: Aged; Calcium - blood; Diphosphonates - administration & dosage; Diphosphonates - pharmacokinetics; Diphosphonates - therapeutic use; Female; Homeostasis; Humans; Hypercalcemia; Hypercalcemia - drug therapy; Hypercalcemia - etiology; Infusions, Intravenous; Kinetics; Male; Middle Aged; Neoplasms - complications; Osteocalcin - blood; Pamidronate; Parathyroid Hormone - blood; Parathyroid Hormone-Related Protein; Pharmacokinetics; Proteins - metabolism; PTH related peptide
• ISSN: 0918-8959; 1348-4540
• DOI: 10.1507/endocrj.41.655

The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia. Eight patients with tumor-associated hypercalcemia received intravenous infusion of pamidronate (45 mg) and their high mean serum calcium concentration significantly decreased from 3.56 mmol/L to 2.62 mmol/L 7 days after treatment. Serum intact PTH before treatment had been suppressed to below normal in all patients but returned to normal range in six patients within 7 days after treatment. Urinary PTH related peptide (PTHrP) excretion before treatment had been elevated in seven patients and then significantly increased further after pamidronate therapy. The serum bone Gla protein concentration was not apparently changed by the treatment. Pamidronate in serum was rapidly eliminated after the treatment and urinary excretion reached a plateau on the second day (13.8% of the administered dose), suggesting that the major portion of the infused dose had been distributed to the bone and other tissues. These findings suggest that pamidronate has a potent hypocalcemic effect and that PTHrP production in malignant tumors could be affected by pamidronate therapy.